Home » Newsletters » BioWorld Science

BioWorld Science

March 5, 2004

View Archived Issues

Anti-TNF-alpha dAb potent in rheumatoid arthritis model

Antiinflammatory and antithrombotic effects of pravastatin in diabetic patients

Good safety and pharmacokinetic profile found for a buccal testosterone formulation

Positive preclinical progress for ENT-103

Uroxatral launched to primary-care physicians

Hudson Health Sciences licenses novel radiosensitizer IPdR

Chiron and Xoma collaborate to develop therapeutic antibodies for cancer

CARDIOsphere successfully completes two pivotal studies

Promising effects and safety profile found for PT-141 in erectile dysfunction

Effective prevention of migraine headache with topiramate

Improved therapeutic index for AP-5280 in vitro and in vivo as compared to carboplatin

Endo in license agreement with MakScientific for selective CB2 receptor agonists

Once-daily regimen approved for Floxin Otic for otitis externa

South African Ampligen study cleared to begin

Phase I study evaluates IDEA-070 for skin inflammation and pain

Long-term survival data for Rencarex in metastatic renal cell carcinoma

Patient dosing commences in phase II trial of AeroLEF

Chiron to discuss details of upcoming tifacogin phase III trial

Novel class of HCV protease inhibitors evaluated by Lilly

BMS researchers identify novel VEGFR2 and FGFR1 inhibitors

New KSP inhibitors in early development at Cytokinetics

Novel NK1 antagonists designed by Merck scientists

Boehringer Ingelheim claims new TK inhibitors for cancer and other proliferative disorders

New glucocorticoid receptor modulators covered by BMS patent

French team identifies ghrelin analogues as GHS receptor ligands

New gamma-secretase inhibitors reported by Sanofi-Synthelabo researchers

European orphan drug status for Revlimid in MDS

European approval for Advate